In the modern era of medicine, advances in antibiotics have saved countless lives, effectively treating diseases caused by pathogens such as Streptococcus pneumoniae, Neisseria gonorrhoeae and Campylobacter Jejuni. However, these micro-organisms, which are responsible for serious diseases such as pneumonia, gonorrhoea and intestinal diseases, are evolving towards an alarming future: they are increasingly resistant to conventional treatments. Concern about antibiotic resistance is on the rise, and it is a growing threat to global health.
Faced with this critical scenario, we at HIFAS Biologics have immersed ourselves in the search for innovative solutions. Through in-depth fungal research, we have succeeded in developing fungal-derived samples that promise to be potential candidates for new drug development, tackling antibiotic resistance and fighting for global health.
Streptococcus pneumoniae.
This pathogen is a major cause of bacterial pneumonia, a disease that can be fatal if not properly treated. As antibiotic resistance continues to increase, it is becoming imperative to find new treatments. Studies at HIFAS have identified fungi with potent antimicrobial properties that could be key to the development of new antibiotics effective against this pathogen.
Neisseria gonorrhoeae.
Gonorrhoeae is a common sexually transmitted infection that, if left untreated, can lead to serious complications, including infertility. The increasing resistance of Neisseria gonorrhoeae to existing antibiotics has raised the urgency of finding treatment alternatives. The fungi we have studied show promising abilities to combat this resistant bacterium, opening up new therapeutic possibilities.
Campylobacter Jejuni.
Este patógeno es una causa común de enfermedades intestinales, provocando síntomas como diarrea, fiebre y dolor abdominal. La resistencia a los antibióticos en Campylobacter Jejuni es otra preocupación creciente en salud pública. En HIFAS Biologics hemos identificado hongos con potencial para desarrollar nuevos tratamientos que puedan combatir eficazmente esta bacteria y reducir su impacto en la salud humana.
Así, nuestro compromiso con la innovación y la investigación con hongos ofrece una nueva esperanza en la lucha contra la resistencia microbiana. Aprovechando el poder de la naturaleza y la ciencia, en HIFAS estamos trabajando incansablemente para desarrollar nuevos antibióticos que puedan tratar eficazmente las infecciones causadas por estos patógenos resistentes, protegiendo así la salud y el bienestar de las personas en todo el mundo.